PRINCETON, N.J., April 26 /PRNewswire-FirstCall/ -- Pharmacopeia , an innovator in the discovery and development of novel small molecule therapeutics, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2007, after the close of market on Thursday, May 10, 2007. The Company will conduct a webcast and conference call at 5:00 p.m. EDT on the same day.
Dr. Leslie J. Browne, President and Chief Executive Officer, and Mr. Brian M. Posner, Executive Vice President and Chief Financial Officer, will host the call. Forward-looking and other material information may be discussed on this conference call.
Date: May 10, 2007
Time: 5:00 p.m. EDT
Webcast: Accessible via the Company’s website at http://www.pharmacopeia.com
Domestic callers: (800) 500-0311
International callers: (719) 457-2698
Confirmation code: 4666647
Name of conference: Pharmacopeia’s First Quarter 2007 Financial Results Conference Call
A replay of the conference call can be accessed by dialing toll-free (888) 203-1112 in the U.S., or (719) 457-0820 outside the U.S. The access code for the replay is 4666647. Replay of the webcast will also be accessible on Pharmacopeia’s website on the Investors page at www.pharmacopeia.com. The replays will be available for two weeks.
Contact: Amy P. Sharpless (609) 452-3643 irreq@pcop.com
ABOUT PHARMACOPEIA
Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia’s most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia’s collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development. Pharmacopeia’s current strategic partnerships are with Cephalon, GlaxoSmithKline, Organon and Wyeth.
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia’s Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.
Pharmacopeia
CONTACT: Amy P. Sharpless for Pharmacopeia, +1-609-452-3643,irreq@pcop.com
Web site: http://www.pharmacopeia.com/
